SPTLC2 Gene Mutation Detection for Sensory Neuropathy Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing hereditary sensory neuropathies (HSNs) are inadequate, as they fail to identify a significant portion of patients with pathogenic mutations and do not provide insights into the underlying pathogenesis, leading to variable treatment responses and high morbidity.
Innovation Solution
The identification of nucleic acid variations in the SPTLC2 gene, which are associated with sensory neuropathies, allowing for a reliable diagnosis and prediction of sensory neuropathy-related diseases through genetic markers, enabling personalized medicine approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for hereditary sensory neuropathies, then the diagnostic process is simple and quick, but the diagnostic accuracy is insufficient and fails to identify a significant portion of patients
Solution Approach 1:
The patent replaces conventional clinical diagnostic methods with molecular genetic testing. Specifically, it uses PCR (polymerase chain reaction) and sequencing techniques to detect mutations in the SPTLC2 gene, substituting the mechanical/clinical examination process with a molecular biology-based system that provides higher diagnostic accuracy.
Solution Approach 2:
The patent changes the diagnostic parameter from clinical symptoms and physical examination findings to molecular genetic markers. By detecting specific nucleic acid variations (mutations) in the SPTLC2 gene, the diagnostic system transitions from evaluating phenotypic characteristics to analyzing genotypic characteristics, thereby improving measurement precision.
2Reliability
If genetic testing for SPTLC2 mutations is implemented, then diagnostic accuracy and prediction capability are improved, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent extracts and focuses on a specific gene (SPTLC2) and its mutations rather than conducting comprehensive genetic screening. By isolating the diagnostic focus to this single gene with known pathogenic mutations, the system achieves high reliability for sensory neuropathy diagnosis while limiting the complexity to a targeted testing approach rather than full genomic analysis.
3Quantity of substance
If comprehensive genetic screening is performed to identify all patients, then the quantity of identified patients increases, but the cost and time required for testing increases
Solution Approach 1:
The patent performs preliminary identification of at-risk individuals through family history assessment and clinical evaluation before initiating genetic testing. This preliminary action allows for prioritization of testing in high-risk families, thereby increasing the quantity of identified patients efficiently while reducing overall testing time by focusing resources on the most likely candidates.
Data Source
AI summary
Described are methods and kits for identifying a subject at risk of, or having, a sensory neuropathy related disease, such as sensory neuropathies. In particular, the disclosure is based on the determination of mutations in the SPTLC2 gene causing sensory neuropathies.